Brief: Corline Biomedical applies for Orphan Drug status for Renaparin at FDA
Nov 3 (Reuters) - Corline Biomedical AB CLBIO.ST :
* Applies for Orphan Drug status for Renaparin at U.S. Food and Drug Administration (FDA)
Source text for Eikon: ID:nHUG2Q9V7J
Further company coverage: CLBIO.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))
Recent news on Corline Biomedical AB
See all newsBrief: Corline Biomedical Expectes Positive EBITDA In 2027
Brief: Corline Biomedical: Canada To Grant Kardium Up To C$31.25 Mln For Manufacturing Capacity Expansion
Brief: Corline Biomedical Q2 Net Sales Amount To SEK 4.7 Million
Brief: Corline Biomedical Partner Kardium Receives Approval For Globe Pulsed Field System In Canada
Brief: Corline Biomedical Q1 Result After Financial Items At SEK -2.5 Mln